ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,680 | +74.0% | 2,000 | +100.0% | 0.00% | 0.0% |
| Q2 2023 | $23,950 | +27.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $18,820 | +18.2% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $15,920 | -0.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $16,000 | +14.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $14,000 | -41.7% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $24,000 | +4.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $23,000 | -8.0% | 1,000 | -33.7% | 0.00% | 0.0% |
| Q3 2021 | $25,000 | -32.4% | 1,508 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $37,000 | -5.1% | 1,508 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $39,000 | -51.9% | 1,508 | 0.0% | 0.00% | -57.1% |
| Q4 2020 | $81,000 | +30.6% | 1,508 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $62,000 | +158.3% | 1,508 | +201.6% | 0.01% | +133.3% |
| Q2 2020 | $24,000 | +14.3% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $21,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |